全文获取类型
收费全文 | 183篇 |
免费 | 18篇 |
专业分类
儿科学 | 2篇 |
妇产科学 | 43篇 |
基础医学 | 20篇 |
口腔科学 | 3篇 |
临床医学 | 25篇 |
内科学 | 28篇 |
皮肤病学 | 2篇 |
神经病学 | 9篇 |
特种医学 | 8篇 |
外科学 | 21篇 |
综合类 | 1篇 |
预防医学 | 5篇 |
眼科学 | 8篇 |
药学 | 12篇 |
肿瘤学 | 14篇 |
出版年
2023年 | 2篇 |
2021年 | 5篇 |
2020年 | 6篇 |
2019年 | 8篇 |
2018年 | 3篇 |
2017年 | 8篇 |
2016年 | 4篇 |
2015年 | 4篇 |
2014年 | 7篇 |
2013年 | 20篇 |
2012年 | 7篇 |
2011年 | 12篇 |
2010年 | 8篇 |
2009年 | 12篇 |
2008年 | 14篇 |
2007年 | 26篇 |
2006年 | 16篇 |
2005年 | 15篇 |
2004年 | 8篇 |
2003年 | 6篇 |
2002年 | 4篇 |
2001年 | 3篇 |
2000年 | 1篇 |
1997年 | 1篇 |
1996年 | 1篇 |
排序方式: 共有201条查询结果,搜索用时 187 毫秒
1.
Shin‐Lei Peng Chih‐Feng Chen Ho‐Ling Liu Chun‐Chung Lui Yu‐Jie Huang Tsung‐Han Lee Chiung‐Chih Chang Fu‐Nien Wang 《NMR in biomedicine》2013,26(4):443-450
Dynamic contrast‐enhanced MRI (DCE MRI) has been used to study tumor response to treatment for many years. In this study, the modified full width at half‐maximum (mFWHM), calculated from the wash‐in slope histogram, is proposed as a parameter for the evaluation of changes in tumor heterogeneity which respond to radiotherapy. Twenty‐five patients with brain tumors were evaluated and divided into the nonresponder group (n = 11) and the responder group (n = 14) according to the Response Evaluation Criteria in Solid Tumors (RECIST). All selected tumors were evaluated by mFWHM ratios of post‐ to pre‐therapy (the ratio was defined as the therapeutic mFWHM ratio, TMR). The changes in kurtosis of the histograms and the averaged Ktrans within a tumor were also calculated for comparison. The receiver operating characteristic analysis and Kaplan–Meier curves were used to examine the diagnosis ability. The TMR values were significantly higher in nonresponders than in responders (p < 0.001). When compared with the other two parameters, the proposed method also demonstrated better sensitivity and specificity. When adopting the TMR for the estimation of prognosis after therapy, there was a significant difference between the population survival curves. In conclusion, the derived mFWHM reflects tumor heterogeneity, and the ability to depict patient survival probability from TMR corresponds well with that from RECIST. The results reveal that, in brain tumors, progression may be exhibited not only by tumor size, but also by tumor heterogeneity. Copyright © 2012 John Wiley & Sons, Ltd. 相似文献
2.
3.
4.
Guang‐Yuan Mar Ming‐Ting Chou Hsien‐Hui Chung Nien‐Hua Chiu Mei‐Fen Chen Juei‐Tang Cheng 《International journal of experimental pathology》2013,94(1):17-24
The role of imidazoline receptors in the regulation of vascular function remains unclear. In this study, we evaluated the effect of agmatine, an imidazoline receptor agonist, on systolic blood pressure (SBP) in spontaneously hypertensive rats (SHRs) and investigated the expressions of imidazoline receptors by Western blot. The isometric tension of aortic rings isolated from male SHRs was also estimated. Agmatine decreased SBP in a dose‐dependent manner in SHRs but not in the normal group [Wistar–Kyoto (WKY) rats]. This reduction in SBP in SHRs was abolished by BU224, a selective antagonist of imidazoline I2‐receptors. Higher expression of imidazoline receptors in SHR was observed. Moreover, agmatine‐induced relaxation in isolated aortic rings precontracted with phenylephrine or KCl. This relaxation was also abolished by BU224 but was not modified by efaroxan, an imidazoline I1‐receptor antagonist. Agmatine‐induced relaxation was also attenuated by PNU 37883, a selective blocker of vascular ATP‐sensitive potassium (KATP) channels. Additionally, vasodilatation by agmatine was reduced by an inhibitor of protein kinase A (PKA). We suggest that agmatine can lower blood pressure in SHRs through activation of the peripheral imidazoline I2‐receptor, which is expressed more highly in SHRs. 相似文献
5.
6.
7.
Comparison of systemic therapies used concurrently with radiation for the treatment of human papillomavirus–associated oropharyngeal cancer
下载免费PDF全文
![点击此处可从《Head & neck》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Hsin‐Hua Nien MD Erich M. Sturgis MD Merrill S. Kies MD Adel K. El‐Naggar MD William H. Morrison MD Beth M. Beadle MD PhD Faye M. Johnson MD Gary B. Gunn MD Clifton D. Fuller MD PhD Jack Phan MD PhD Kathryn A. Gold MD Steven J. Frank MD Heath Skinner MD PhD David I. Rosenthal MD Adam S. Garden MD 《Head & neck》2016,38(Z1):E1554-E1561
8.
Han YM Romero R Kim YM Kim JS Richani K Friel LA Kusanovic JP Jeanty C Vitale S Nien JK Espinoza J Kim CJ 《The Journal of pathology》2007,211(4):489-496
9.
BACKGROUND: To meet recommendations given by the Laboratory Working Group of the National Kidney Disease Education Program for improving serum creatinine measurements, NIST developed standard reference material (SRM) 967 Creatinine in Frozen Human Serum. SRM 967 is intended for use by laboratories and in vitro diagnostic equipment manufacturers for the calibration and evaluation of routine clinical methods. METHODS: The SRM was produced from 2 serum pools with different creatinine concentrations. The concentrations were certified using a higher-order isotope-dilution GC-MS method and an isotope-dilution LC-MS method. The LC-MS method is a potential higher-order reference measurement procedure. RESULTS: The GC-MS mean (CV) concentrations were 67.0 (0.9%) mumol/L for serum pool 1 and 346.1 (0.45%) mumol/L for serum pool 2. The LC-MS results were 66.1 (0.2%) mumol/L and 346.3 (0.2%) mumol/L, respectively. For serum pool 1, there was a 1.4% difference between the mean GC-MS and LC-MS measurements, and a 0.10% difference for serum pool 2. The results from the 2 methods were combined to give the certified concentrations and expanded uncertainties. CONCLUSIONS: The certified concentration (expanded uncertainty) of SRM 967 was 66.5 (1.8) mumol/L for serum pool 1 (a value close to the diagnostically important concentration of 88.4 mumol/L) and 346.2 (7.4) mumol/L for serum pool 2 (a concentration corresponding to that expected in a patient with chronic kidney disease). 相似文献
10.
Plasma adiponectin concentrations in non-pregnant, normal and overweight pregnant women 总被引:1,自引:0,他引:1
Nien JK Mazaki-Tovi S Romero R Erez O Kusanovic JP Gotsch F Pineles BL Gomez R Edwin S Mazor M Espinoza J Yoon BH Hassan SS 《Journal of perinatal medicine》2007,35(6):522-531
AIMS: Adiponectin is an adipokine that has anti-diabetic, anti-atherogenic, anti-inflammatory and angiogenic properties. This hormone has been implicated in both the physiological adaptation to normal pregnancy and in obstetrical complications. The aims of this study were to determine normal maternal plasma concentrations of adiponectin throughout gestation and to explore the relationships between plasma adiponectin concentration, pregnancy, and maternal overweight. METHODS: A cross-sectional study was designed to include normal pregnant (normal weight and overweight; 11-42 weeks of gestation), and non-pregnant women. Plasma adiponectin concentration was determined by immunoassay. Non-parametric statistics were used for analysis. RESULTS: (1) Adiponectin was detectable in the plasma of all patients; (2) there was no significant differences in the median adiponectin concentration between pregnant and non-pregnant women; (3) plasma adiponectin concentrations were negatively correlated with gestational age only among normal weight pregnant women; and (4) overweight patients had significantly lower plasma adiponectin concentrations than normal weight women. CONCLUSIONS: Consistent with the increased insulin resistance and weight gain that occur in pregnancy, adiponectin concentrations were negatively correlated with gestational age. The results of this study and the nomogram herein presented, can serve as the basis to explore the relationship between adiponectin and pregnancy complications and facilitate the clinical use of this important adipokine. 相似文献